REMARKS

The listed references were brought to applicants' attention by the attached European Search Report dated August 6, 2003. Each reference was first cited in this search report from the European Patent Office, in the counterpart European Application number EP 01 11 6197, not more than three months prior to the filing of the present information disclosure statement.

FR 6 518 M discloses liposoluble organic copper salts of anti-inflammatory medical compounds, suitable for oral administration. These retain their efficacy, yet the formulations show reduced secondary effects typically associated with copper salts administered orally.

EP 0 702 953 A has English language counterparts US 5,990,152 and US 6,348,490.

DE 44 19 783 discloses a shampoo for treatment and care of hair containing 0.2-10% of an oxidized or reduced enantiomer of alpha-lipoic acid, dihydrolipoic acid (racemate) or their esters, 6,8-bis-nor-lipoic acid, tetra-nor-lipoic acid, or 1,2-dithiacyclopentane-3-butylsulphonic acid or their alkali metal salts, and one or more combination partners including selenium salts, disodium salts, potassium salts or a condensation product of lauric acid and protein hydrolysate, palm-kernel fatty acid sarcoside of methyltaurine, palm kernel oil fatty acid sarcoside of triethanolamine, sodium salt of a condensation product of undecylenic acid, water-soluble vitamin E or F, ascorbic acid, beer extract, camomile flower extract or dye concentrates.

DE 1 668 887 discloses calcium salts of thioctic acid with increased stability over prior art compositions of thioctic acid, known to be useful in treating liver disease.

US 5,292,538, Patent Abstracts of Japan vol. 012, no. 022 (C-470) (JP 62 175 417), and WO 01/66560 are all in the English language.

A check is enclosed to cover the required fee under 37 CFR §1.97(d).

Entry is respectfully solicited.

Respectfully submitted,

KEIL & WEINKAUF

David C. Liechty Reg. No. 48,692

1350 Connecticut Ave., N.W. Washington, D.C. 20036 (202)659-0100

DCL/kas